Sutro Biopharma, Inc. and Blackstone announced the companies have entered into a royalty financing collaboration agreement where funds managed by Blackstone Life Sciences will provide $140 million upfront, with up to an additional $250 million in future milestone payments triggered at various return thresholds, in exchange for Sutroâs 4% royalty, or revenue interest, in the potential future sales of Vaxcyteâs products, including VAX-24 and other products that Vaxcyte develops under its license with Sutro. Vaxcyteâs lead candidate, VAX-24, is a Phase 3 ready, 24-valent next-generation pneumococcal conjugate vaccine (PCV) with enhanced serotype coverage and immunogenicity. Vaxcyteâs PCV franchise is enabled by Sutroâs XpressCF® cell-free protein synthesis technology.
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
123 USD | -2.90% | -3.35% | -5.59% |
07:38pm | Ixico wins deal; United Oil & Gas settles debt | AN |
May. 22 | News Highlights : Top Financial Services News of the Day - Wednesday at 4 PM ET | DJ |
Stocks mentioned in the article
Price
|
Change
|
5d. change
|
Capi.
| ||
---|---|---|---|---|---|
123 USD | -2.93% | -3.35% | 96.17B | ||
4.055 USD | -4.81% | -2.65% | 348M | ||
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
-5.59% | 96.17B | |
+25.70% | 93.86B | |
+21.13% | 28.18B | |
-2.35% | 18.72B | |
+7.68% | 15.73B | |
+14.94% | 15.48B | |
-22.59% | 12.5B | |
+26.28% | 9.84B | |
+19.41% | 9.74B | |
+28.33% | 7.37B |
- Stock Market
- Equities
- BX Stock
- News Blackstone Inc.
- Sutro Biopharma and Blackstone Announces Royalty Financing Collaboration